Last reviewed · How we verify

Mizoribine (MZR)

Asahi Kasei Pharma Corporation · Phase 3 active Small molecule

Mizoribine (MZR) is a IMPDH inhibitor; immunosuppressant Small molecule drug developed by Asahi Kasei Pharma Corporation. It is currently in Phase 3 development for Prevention of organ transplant rejection, Autoimmune and inflammatory diseases. Also known as: HE-69.

Mizoribine inhibits inosine monophosphate dehydrogenase (IMPDH) to suppress guanine nucleotide synthesis and reduce T and B cell proliferation.

Mizoribine inhibits inosine monophosphate dehydrogenase (IMPDH) to suppress guanine nucleotide synthesis and reduce T and B cell proliferation. Used for Prevention of organ transplant rejection, Autoimmune and inflammatory diseases.

At a glance

Generic nameMizoribine (MZR)
Also known asHE-69
SponsorAsahi Kasei Pharma Corporation
Drug classIMPDH inhibitor; immunosuppressant
TargetIMPDH (inosine monophosphate dehydrogenase)
ModalitySmall molecule
Therapeutic areaImmunology; Transplantation
PhasePhase 3

Mechanism of action

Mizoribine is an inosine monophosphate dehydrogenase (IMPDH) inhibitor that selectively depletes guanosine nucleotides in lymphocytes, thereby suppressing T cell and B cell proliferation. This immunosuppressive mechanism makes it useful in preventing organ transplant rejection and treating autoimmune conditions. The drug preferentially affects lymphocytes because they rely heavily on the de novo pathway of guanine nucleotide synthesis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Mizoribine (MZR)

What is Mizoribine (MZR)?

Mizoribine (MZR) is a IMPDH inhibitor; immunosuppressant drug developed by Asahi Kasei Pharma Corporation, indicated for Prevention of organ transplant rejection, Autoimmune and inflammatory diseases.

How does Mizoribine (MZR) work?

Mizoribine inhibits inosine monophosphate dehydrogenase (IMPDH) to suppress guanine nucleotide synthesis and reduce T and B cell proliferation.

What is Mizoribine (MZR) used for?

Mizoribine (MZR) is indicated for Prevention of organ transplant rejection, Autoimmune and inflammatory diseases.

Who makes Mizoribine (MZR)?

Mizoribine (MZR) is developed by Asahi Kasei Pharma Corporation (see full Asahi Kasei Pharma Corporation pipeline at /company/asahi-kasei-pharma-corporation).

Is Mizoribine (MZR) also known as anything else?

Mizoribine (MZR) is also known as HE-69.

What drug class is Mizoribine (MZR) in?

Mizoribine (MZR) belongs to the IMPDH inhibitor; immunosuppressant class. See all IMPDH inhibitor; immunosuppressant drugs at /class/impdh-inhibitor-immunosuppressant.

What development phase is Mizoribine (MZR) in?

Mizoribine (MZR) is in Phase 3.

What are the side effects of Mizoribine (MZR)?

Common side effects of Mizoribine (MZR) include Leukopenia, Gastrointestinal disturbances, Infection, Hepatotoxicity.

What does Mizoribine (MZR) target?

Mizoribine (MZR) targets IMPDH (inosine monophosphate dehydrogenase) and is a IMPDH inhibitor; immunosuppressant.

Related